Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CDA | P32320 | 1/20 | 0.49 |
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113147 | 1.00 | MAPT (0.49) | MAPTCDAADKDOT1LALDH1A1 | |
| SCHEMBL15670883 | 0.78 | LMNA (0.56) | MAPTCDADOT1LALDH1A1LMNA | |
| SCHEMBL3851144 | 0.78 | LMNA (0.56) | MAPTCDADOT1LALDH1A1LMNA | |
| SCHEMBL1520633 | 0.78 | MAPT (0.52) | MAPTCDADOT1LALDH1A1LMNA | |
| SCHEMBL30495894 | 0.73 | SMN1; SMN2 (0.51) | MAPTCDAADKDOT1LALDH1A1 | |
| SCHEMBL4854235 | 0.73 | MAPT (0.50) | MAPTCDADOT1LALDH1A1LMNA | |
| SCHEMBL18986084 | 0.73 | MAPT (0.50) | MAPTCDADOT1LALDH1A1LMNA | |
| SCHEMBL30411899 | 0.72 | SMN1; SMN2 (0.50) | MAPTCDAADKDOT1LALDH1A1 | |
| SCHEMBL9698994 | 0.71 | ALDH1A1 (0.47) | MAPTCDAADKDOT1LALDH1A1 | |
| SCHEMBL13065920 | 0.71 | SMN1; SMN2 (0.56) | MAPTCDAALDH1A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352777-A1 | SUBMUCOSAL BIORESORBABLE DRUG ELUTING PLATFORM | INTERSECT ENT INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12403291-B2 | Submucosal bioresorbable drug eluting platform | INTERSECT ENT, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-3791826-B1 | SELF-EXPANDING DEVICES | INTERSECT ENT INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-12064577-B2 | Drug-coated balloon | INTERSECT ENT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240269350-A1 | IMPLANTABLE MATRIX FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | LYRA THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240050632-A1 | SELF-EXPANDING DEVICES AND METHODS THEREFOR | INTERSECT ENT, INC | 2024-02-15 | — | — | US | disclosed |
| EP-3936166-B1 | DRUG-COATED EXPANDABLE DEVICE FOR TREATING A NASAL, AN OTIC, OR A THROAT CONDITION | INTERSECT ENT INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230389690-A1 | PERSONAL CLEANSING WAND | Silicon Valley Innovations, Inc. | 2023-12-07 | — | — | US | disclosed |
| US-11826494-B2 | Self-expanding devices and methods therefor | INTERSECT ENT, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220168465-A1 | BIODEGRADABLE NASAL SPLINT | SEPTUM SOLUTIONS, LLC | 2022-06-02 | — | — | US | disclosed |
| US-20220104611-A1 | PERSONAL CLEANSING WAND | Silicon Valley Innovations, Inc. | 2022-04-07 | — | — | US | disclosed |
| US-20220072798-A1 | Systems And Methods For Forming A Customized Therapeutic Support | MATHENY ENTERPRISES, LLC | 2022-03-10 | — | — | US | disclosed |
| US-20220054405-A1 | SUBMUCOSAL BIORESORBABLE DRUG ELUTING PLATFORM | INTERSECT ENT, INC. | 2022-02-24 | — | — | US | disclosed |
| CN-102448959-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| CN-102307872-A | BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBOTT LAB | 2012-01-04 | — | — | CN | disclosed |
| CN-102307622-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-01-04 | — | — | CN | disclosed |
| CN-101500579-A | Methods and compositions for inhibiting IMPDH isoform 1 | UNIV JOHNS HOPKINS (US) | 2009-08-05 | — | — | CN | disclosed |
| US-5126361-A | Antitumor agentss | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1992-06-30 | — | — | US | disclosed |
| US-5059590-A | Antitumor agents | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1991-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | MAPT 2865/4885CDA 4869/4885ADK 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.